Cargando…
Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
INTRODUCTION: Several studies have shown increased incidence, recurrence, and severity of Clostridium difficile infection (CDI) over the last decade. Patients with inflammatory bowel disease (IBD) who develop CDI are more prone to morbidity and mortality than CDI in patients without IBD. This study...
Autores principales: | Saad Alshahrani, Abdulaziz, Mohammad, Danah, attieh Alzahrani, Mohammad, Narula, Neeraj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448164/ https://www.ncbi.nlm.nih.gov/pubmed/37638216 http://dx.doi.org/10.1016/j.jsps.2023.101736 |
Ejemplares similares
-
Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020) -
Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020) -
Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
por: Crooks, Benjamin, et al.
Publicado: (2020) -
Effect of obesity on vedolizumab response in inflammatory bowel disease
por: Levine, Louis J., et al.
Publicado: (2022) -
Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
por: Poylin, Vitaliy Y., et al.
Publicado: (2022)